Healio5d
Six-month asthma control score on mepolizumab predicts remission in eosinophilic asthma
Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...
Options Available For Adolescents With Asthma At BioBehavioral Research Of Austin
Dr. Neha Reshamwala, owner of Frontier Allergy, Asthma & Immunology, with BioBehavioral Research of Austin (BBRA) stopped by ...
The Lancet2d
Chronic obstructive pulmonary disease: new therapies and old needs
Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...
Daily1d
GSK Depemokimab applications accepted for review in China, Japan for asthma with type 2 inflammation, CRSwNP
GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...
The Lancet12d
Social and environmental determinants of health inequities in childhood asthma
Asthma represents a substantial health burden in childhood globally, with minoritised populations being disproportionately impacted.1 Recent literature has increasingly linked social determinants of ...
Pharmabiz4d
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...
PharmiWeb5d
Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...